Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0001209191-23-010876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-17 | 2023-02-15 | PHIO | Kontulis Caitlin | Sec, VP Fin, Admin | F - Tax | $5.20 | -657 | 7,994 | -8% | -$3,416 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2023-02-15 | F | D | 657 | $5.20 | 7,994 | D | — | — | (F2) Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. |